(-)-Eburnamonine is a chemical compound that is found in the plant species like Tabernaemontana divaricata, and Tabernaemontana undulata, and it belongs to the Iboga alkaloid family. It is also known as (18S,20S)-18,19-didehydro-19-methoxyeburnamenine. (-)-Eburnamonine has a molecular formula of C21H26N2O2 with a formula weight of 338.44 g/mol and has a CAS number of 4880-88-0.
Some top keywords associated with (-)-Eburnamonine include Tabernaemontana divaricata, Iboga alkaloids, anti-cancer effects, anti-inflammatory effects, antitumor agent, antiviral agent. Synonyms for (-)-Eburnamonine include 18H-ibogamine, 6, 7-didehydro-19-methoxy-19-oxoeburnamonine, 19-Methoxy-6,7,18,19-tetrahydro-1H,14H-18,20-ethenomethanoibogamine.
(-)-Eburnamonine has been studied for its potential health benefits, including its anti-inflammatory and antitumor properties. It has been found that (-)-Eburnamonine suppresses the growth of cancer cells, especially in prostate cancer. Studies have shown that (-)-Eburnamonine can induce cell cycle arrest, an anti-proliferative effect, and promoting apoptosis, thereby showing anti-cancer effects.
The anti-inflammatory effects of (-)-Eburnamonine have also been studied. A study published in the Journal of Ethnopharmacology found that (-)-Eburnamonine exhibited anti-inflammatory effects by inhibiting an enzyme in the inflammatory pathway. This enzyme inhibition reduces the levels of pro-inflammatory substances responsible for the inflammation. Thus, (-)-Eburnamonine could be used in the treatment of inflammatory-related conditions.
The product mechanism of (-)-Eburnamonine is due to its ability to block DNA synthesis and disrupt microtubule assembly. This property of (-)-Eburnamonine can be useful in the treatment of certain types of cancers.
(-)-Eburnamonine is considered safe for consumption under normal doses, but long-term use and high doses may have potential side effects. Some reported side effects include dizziness, nausea, vomiting, abdominal pain, and hallucinations. However, these side effects occur less frequently when used in the appropriate amounts and under the supervision of a healthcare professional.
Information regarding dosing and administration of (-)-Eburnamonine is limited, and there are no standard guidelines for its dosage. It is recommended to consult with a healthcare professional for dosage recommendations based on individual medical history and overall health.
In conclusion, (-)-Eburnamonine has interesting anti-inflammatory, anti-tumor and anti-cancer effects that have been studied. It has shown efficacy against inflammatory-related conditions and has potential use as an anti-tumor agent, especially in the treatment of prostate cancer. However, more studies are required to determine the optimal dosage, efficiency, and safety of (-)-Eburnamonine before it can be conclusively established that it could be effective in humans. Nevertheless, (-)-Eburnamonine shows promise for potential use as an alternative treatment for certain diseases, and its mechanism of action warrants further exploration by researchers.
